Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patientsNuri Karadurmus a,* , Mehmet Ali Nahit Sendur b, Burcak Karacac, Omer Fatih Olmezd, Ilhan Hacibekiroglu e, Hasan Senol Coskunf, Serkan Degirmencioglu g, Yasemin Kemal h,Saadettin Kilickapi, Ahmet Taner Sumbul j, Burc Aydink, Hande Turnal, Muhammet Ali Kaplanm,Nalan Babacann, Umut Demirci o, Alper Atap, Dilek Erdemq, Ahmet Ozet r, Huseyin Abali sa Health Sciences University, Gulhane Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
b Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
c Ege University, Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey
d Medipol Mega Hospitals Complex, Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
e Sakarya University, Faculty of Medicine, Department of Medical Oncology, Sakarya, Turkey
f Akdeniz University, Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
g Pamukkale University, Faculty of Medicine, Department of Medical Oncology, Denizli, Turkey
h Ondokuz Mayıs University, Faculty of Medicine, Department of Medical Oncology, Samsun, Turkey
i Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey
j Baskent University Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
k Medical Science Liaison, Bristol Myers Squib, Istanbul, Turkey
l Istanbul Cerrahpasa University, Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
m Dicle University, Faculty of Medicine, Department of Medical Oncology, Diyarbakır, Turkey
n MarmaraUniversity, Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
oUniversity of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
p Medical Park Tarsus Hospital, Department of Medical Oncology, Mersin, Turkey
qMedical Park Samsun Hospital, Department of Medical Oncology, Samsun, Turkey
rGazi University, Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
sAcıbadem University, Faculty of Medicine, Department of Medical Oncology, Istanbul, TurkeyDOI: 10.1016/j.jons.2018.10.001 Sayfalar: 125 - 129 1564 Viewed.